Immunome, Inc. announced its plans to commence an underwritten public offering to issue and sell $400 million of shares of its common stock.
The company expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares.
This proposed offering is being made pursuant to a shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission.
Proposed Public Offering
Immunome plans to issue and sell $400 million of its common stock, with a 30-day option for additional shares.
Underwriters
Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs, & Guggenheim Securities are acting as joint bookrunning managers for the offering.
Registration Statement
The offering is being made pursuant to a shelf registration statement on Form S-3 filed with the SEC.
- Immunome is taking a strategic step to raise significant capital through the public offering.
- The involvement of reputable bookrunning managers signifies confidence in the offering.
- The completion and success of the proposed offering will depend on market conditions and regulatory factors.
The public offering marks a crucial move for Immunome to secure funding for its growth and development in cancer therapies.